In vitro & in vivo diagnostic substances Sample Contracts

SCOLR, INC.
Scolr Inc • August 13th, 2003 • In vitro & in vivo diagnostic substances
AutoNDA by SimpleDocs
EXHIBIT 10.31
Stock Purchase Agreement • February 9th, 2005 • Meridian Bioscience Inc • In vitro & in vivo diagnostic substances • Ohio
INDENTURE
Indenture • December 2nd, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 10.17 APPENDIX A TO PARTICIPATION AGREEMENT
Participation Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
EXHIBIT 2
Consulting Agreement • October 24th, 2002 • Caprius Inc • In vitro & in vivo diagnostic substances • Delaware
Recitals
Purchase Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ONCOCYTE CORPORATION
Oncocyte Corp • April 12th, 2024 • In vitro & in vivo diagnostic substances

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full, to subscribe for and purchase from Oncocyte Corporation, a California corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

RECITALS
Voting Agreement • April 16th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.6 SUBSCRIPTION AGREEMENT
Subscription Agreement • September 19th, 2003 • Centrex Inc • In vitro & in vivo diagnostic substances • Oklahoma
AutoNDA by SimpleDocs
among
Agreement and Plan of Merger • February 11th, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 12th, 2024 • Oncocyte Corp • In vitro & in vivo diagnostic substances • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of April 11, 2024, between Oncocyte Corporation, a California corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

AGREEMENT AND PLAN OF MERGER by and among:
Agreement and Plan of Merger • May 15th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • Delaware
RECITALS
Supplemental Indenture • May 10th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
AGREEMENT
Stock Option Agreement • March 29th, 2002 • Quidel Corp /De/ • In vitro & in vivo diagnostic substances • California
BACKGROUND
Securities Purchase Agreement • April 6th, 2006 • Synova Healthcare Group Inc • In vitro & in vivo diagnostic substances • Nevada
Exhibit 10.52 PURCHASE AND SALE AGREEMENT by and between PHL-OPCO, LP, a Delaware limited partnership, as Seller,
Purchase and Sale Agreement • March 28th, 2001 • Medtox Scientific Inc • In vitro & in vivo diagnostic substances • Minnesota
ARTICLE I THE LOAN --------
Loan Agreement • March 26th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
AGREEMENT JOINT FILING OF SCHEDULE 13D The undersigned hereby agrees to jointly prepare and file with regulatory authorities a Schedule 13D and any future amendments thereto reporting each of the undersigned's ownership of securities of Neoprobe...
Agreement • March 8th, 2000 • Aries Financial Services Inc • In vitro & in vivo diagnostic substances

The undersigned hereby agrees to jointly prepare and file with regulatory authorities a Schedule 13D and any future amendments thereto reporting each of the undersigned's ownership of securities of Neoprobe Corp., and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned.

BACKGROUND ----------
Revolving Credit Agreement • November 24th, 1997 • Centocor Diagnostics Inc • In vitro & in vivo diagnostic substances • Pennsylvania
RECITAL
Registration Rights Agreement • February 11th, 2005 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances
CENTOCOR, INC.
Underwriting Agreement • January 22nd, 1996 • Centocor Inc • In vitro & in vivo diagnostic substances • New York
BY AND AMONG
Agreement and Plan of Merger • June 18th, 2001 • Lexicon Genetics Inc/Tx • In vitro & in vivo diagnostic substances • Delaware
Time is Money Join Law Insider Premium to draft better contracts faster.